Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

27 trials with published results (7%)

Research Maturity

195 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

1.5%

6 terminated out of 395 trials

Success Rate

97.0%

+10.5% vs benchmark

Late-Stage Pipeline

45%

179 trials in Phase 3/4

Results Transparency

14%

27 of 195 completed with results

Key Signals

27 with results97% success

Data Visualizations

Phase Distribution

315Total
Not Applicable (97)
Early P 1 (4)
P 1 (19)
P 2 (16)
P 3 (35)
P 4 (144)

Trial Status

Completed195
Unknown120
Recruiting35
Not Yet Recruiting20
Withdrawn7
Active Not Recruiting7

Trial Success Rate

97.0%

Benchmark: 86.6%

Based on 195 completed trials

Clinical Trials (395)

Showing 20 of 20 trials
NCT06397066CompletedPrimary

White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection

NCT07746934Not ApplicableNot Yet RecruitingPrimary

Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

NCT05250050Phase 4WithdrawnPrimary

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

NCT07729293Not ApplicableNot Yet RecruitingPrimary

Pylori Duo for Adjunctive Treatment and Prevention of Recurrence of Helicobacter Pylori Infection

NCT07704255Phase 4RecruitingPrimary

Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection

NCT05762991RecruitingPrimary

Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion

NCT07516262RecruitingPrimary

Effect of PPIs on Stool DNA Test for H. Pylori

NCT07624422Phase 4Not Yet RecruitingPrimary

Vonoprazan High-Dose Dual VS Levofloxacin Concomitant

NCT07439445Not ApplicableRecruitingPrimary

Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication

NCT05495854Not ApplicableTerminatedPrimary

New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool

NCT06382493Not ApplicableRecruitingPrimary

Tegoprazan-containing Sequential for H. Pylori

NCT07537634Phase 4RecruitingPrimary

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

NCT05332444Phase 4RecruitingPrimary

Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection

NCT06561711Phase 4CompletedPrimary

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment

NCT07122284Completed

Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity

NCT07458490Not Yet Recruiting

Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound

NCT06340334Not ApplicableCompletedPrimary

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

NCT06412588Not ApplicableCompletedPrimary

Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

NCT06529159Not ApplicableRecruitingPrimary

H. Pylori Eradication With Argon Plasma During Endoscopy

NCT06340724Phase 3CompletedPrimary

Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication

Scroll to load more

Research Network

Activity Timeline